Induction of apoptosis by taxol and cisplatin and effect on cell cycle-related proteins in cisplatin-sensitive and -resistant human ovarian cells

被引:0
|
作者
N Zaffaroni
R Silvestrini
L Orlandi
A Bearzatto
D Gornati
R Villa
机构
[1] Istituto Nazionale per lo Studio e la Cura dei Tumori,Divisione di Oncologia Sperimentale C
来源
British Journal of Cancer | 1998年 / 77卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The effect of taxol (TX) and cisplatin (CDDP), singly or in association, was assessed on two human ovarian cancer cell lines, one sensitive (A2780) and one resistant (A2780 cp8) to CDDP. Cell lines showed a similar sensitivity to TX, whereas different cytotoxicity results were obtained in the two cell lines as a function of TX and CDDP sequence. Specifically, TX followed by CDDP induced simply additive effects in both cell lines, whereas the opposite sequence produced antagonistic effects in A2780 cells and synergistic effects in A2780 cp8 cells. TX, with or without CDDP, induced oligonucleosomal DNA fragmentation typical of the apoptotic process, but the biochemical mechanisms undergoing apoptosis were different in the two cell lines. In fact, in A2780 cells, TX (with or without CDDP) treatment markedly increased p53 as well as p21waf1 protein expression. In A2780 cp8 cells, drug treatment enhanced p53 levels, whereas the expression of p21waf1 was always undetectable at mRNA and protein levels. In the latter cell line, a premature activation of p34cdc2 kinase was observed in correspondence with the drug-induced increase in the S-phase cell fraction. Such an activation was not ascribable to an increase in the overall expression of p34cdc2 or cyclin B1 proteins, but to a dephosphorylation of p34cdc2 kinase. Overall, our results indicate that TX-induced apoptosis in human ovarian cancer cells may be sustained by different events at the cell cycle-control level.
引用
收藏
页码:1378 / 1385
页数:7
相关论文
共 50 条
  • [21] Effects of carfilzomib alone and in combination with cisplatin on the cell death in cisplatin-sensitive and cisplatin-resistant ovarian carcinoma cell lines
    Zarei, S.
    Reza, Zavar J.
    Jaliani, Zarei H.
    Hajizadeh, M. R.
    Sargazi, S.
    Hosseinian, H.
    BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY, 2019, 120 (06): : 468 - 475
  • [22] Modulation of the expression of folate cycle enzymes and polyamine metabolism by berberine in cisplatin-sensitive and -resistant human ovarian cancer cells
    Marverti, Gaetano
    Ligabue, Alessio
    Lombardi, Paolo
    Ferrari, Stefania
    Monti, Maria Giuseppina
    Frassineti, Chiara
    Costi, Maria Paola
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2013, 43 (04) : 1269 - 1280
  • [23] Distamycin A and derivatives as synergic drugs in cisplatin-sensitive and -resistant ovarian cancer cells
    Marverti, Gaetano
    Guaitoli, Giambattista
    Ligabue, Alessio
    Frassineti, Chiara
    Monti, Maria Giuseppina
    Lombardi, Paolo
    Costi, Maria Paola
    AMINO ACIDS, 2012, 42 (2-3) : 641 - 653
  • [24] Role of ERK nuclear translocation in cisplatin-sensitive and -resistant ovarian cancer cells
    Dilruba, S.
    Kalayda, G. V.
    Jaehde, U.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 34 - 34
  • [25] EFFECT OF MODULATION OF PROTEIN-KINASE-C ACTIVITY ON CISPLATIN CYTOTOXICITY IN CISPLATIN-RESISTANT AND CISPLATIN-SENSITIVE HUMAN OSTEOSARCOMA CELLS
    PEREGO, P
    CASATI, G
    GAMBETTA, RA
    SORANZO, C
    ZUNINO, F
    CANCER LETTERS, 1993, 72 (1-2) : 53 - 58
  • [26] Effect of combined treatment of Eribulin with Cisplatin in Cisplatin-sensitive (HEY) and Cisplatin-resistant (HEY-Cis) ovarian cancer cell lines
    Seeber, M.
    Koester, F.
    Polack, S.
    Rody, A.
    Braeutigam, K.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 180 - 180
  • [27] Distamycin A and derivatives as synergic drugs in cisplatin-sensitive and -resistant ovarian cancer cells
    Gaetano Marverti
    Giambattista Guaitoli
    Alessio Ligabue
    Chiara Frassineti
    Maria Giuseppina Monti
    Paolo Lombardi
    Maria Paola Costi
    Amino Acids, 2012, 42 : 641 - 653
  • [28] Mechanism of hyperthermic potentiation of cisplatin action in cisplatin-sensitive and -resistant tumour cells
    JVE Hettinga
    W Lemstra
    C Meijer
    WA Dam
    DRA Uges
    AWT Konings
    EGE De Vries
    HH Kampinga
    British Journal of Cancer, 1997, 75 : 1735 - 1743
  • [29] GALLIC ACID EXHIBITS LOWER CYTOTOXICITY ON NORMAL OVARIAN CELLS THAN CISPLATIN-SENSITIVE AND CISPLATIN-RESISTANT OVARIAN CANCER CELLS
    Al Balushi, N.
    Abdulla, N.
    Al Dhahli, B.
    Hasan, I.
    Dobretsov, S.
    Al Bahlani, S.
    Tsang, B.
    Tamimi, Y.
    Burney, I.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A430 - A430
  • [30] Mechanism of hyperthermic potentiation of cisplatin action in cisplatin-sensitive and -resistant tumour cells
    Hettinga, JVE
    Lemstra, W
    Meijer, C
    Dam, WA
    Uges, DRA
    Konings, AWT
    DeVries, EGE
    Kampinga, HH
    BRITISH JOURNAL OF CANCER, 1997, 75 (12) : 1735 - 1743